Department of Microbiology, Biological Sciences Center, State University of Londrina, Parana, Brazil.
Department of Pathological Sciences, Biological Sciences Center, State University of Londrina, Parana, Brazil.
Curr Pharm Biotechnol. 2019;20(13):1108-1121. doi: 10.2174/1389201020666190809112704.
The epidemiological impact of viral diseases, combined with the emergence and reemergence of some viruses, and the difficulties in identifying effective therapies, have encouraged several studies to develop new therapeutic strategies for viral infections. In this context, the use of immunotherapy for the treatment of viral diseases is increasing. One of the strategies of immunotherapy is the use of antibodies, particularly the monoclonal antibodies (mAbs) and multi-specific antibodies, which bind directly to the viral antigen and bring about activation of the immune system. With current advancements in science and technology, several such antibodies are being tested, and some are already approved and are undergoing clinical trials. The present work aims to review the status of mAb development for the treatment of viral diseases.
病毒疾病的流行病学影响,加上一些病毒的出现和再现,以及难以确定有效的治疗方法,促使许多研究人员开发针对病毒感染的新治疗策略。在这种情况下,免疫疗法在病毒疾病治疗中的应用正在增加。免疫疗法的策略之一是使用抗体,特别是单克隆抗体(mAbs)和多特异性抗体,它们直接与病毒抗原结合,激活免疫系统。随着科学技术的不断进步,正在对几种这样的抗体进行测试,有些已经获得批准并正在进行临床试验。本工作旨在综述单克隆抗体治疗病毒疾病的开发状况。